Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Portfolio Pulse from Benzinga Newsdesk
Trevena, Inc. (NASDAQ:TRVN) has received a $3 million milestone payment from its Chinese partner, Jiangsu Nhwa Pharmaceutical, for the approval of OLINVYK in China.
May 31, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevena receives a $3 million milestone payment from Jiangsu Nhwa Pharmaceutical for the Chinese approval of OLINVYK.
The $3 million milestone payment from Jiangsu Nhwa Pharmaceutical is a positive development for Trevena, as it indicates progress in the commercialization of OLINVYK in China. This could potentially lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100